Suite101

Thalidomide: From Villain to Cancer Fighter - Page 3


© David Olle
Page 3

Apr 30, 2004


References

1. Bartlett, J. et. al. The evolution of thalidomide and its ImiD derivatives as anticancer agents. Nature Reviews Cancer, Vol. 4, No. 4, pp. 314-322 (April 2004) 2. Bartlett, J. et. al. Phase I study to determine the safety, tolerability, and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastic malignant melanoma and other advanced cancers. Brit. J. Cancer, Vol. 90, pp. 955-961 (2004)

3. Coussens, L. and Werb, Z. Inflammation and Cancer. Nature, Vol. 420, No. 6917, pp. 860-7 (Dec. 19-26, 2002)

4. Singhal, S. Antitumor activity of thalidomide in refractory multiple myeloma. New Eng. J. Med., Vol.341, No. 21, pp. 1565-1571 (1999)

Go To Page: 1 2 3


The copyright of the article Thalidomide: From Villain to Cancer Fighter - Page 3 in Cancer Treatment is owned by . Permission to republish Thalidomide: From Villain to Cancer Fighter - Page 3 in print or online must be granted by the author in writing.

Post this Article to facebook Add this Article to del.icio.us! Digg this Article furl this Article Add this Article to Reddit Add this Article to Technorati Add this Article to Newsvine Add this Article to Windows Live Add this Article to Yahoo Add this Article to StumbleUpon Add this Article to BlinkLists Add this Article to Spurl Add this Article to Google Add this Article to Ask Add this Article to Squidoo


about us • limelight blog • writing jobs • careers • press room • site map • terms & conditions • privacy policy • suite101.de